Back to Search Start Over

Monocyte-Platelet Aggregates Triggered by CD31 Molecule in Non-ST Elevation Myocardial Infarction: Clinical Implications in Plaque Rupture.

Authors :
Vinci R
Pedicino D
Bonanni A
d'Aiello A
Pisano E
Ponzo M
Severino A
Ciampi P
Canonico F
Russo G
Di Sario M
Vergallo R
Filomia S
Montone RA
Flego D
Stefanini L
Piacentini R
Conte C
Cribari F
Massetti M
Crea F
Liuzzo G
Source :
Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2022 Jan 25; Vol. 8, pp. 741221. Date of Electronic Publication: 2022 Jan 25 (Print Publication: 2021).
Publication Year :
2022

Abstract

Despite the recent innovations in cardiovascular care, atherothrombosis is still a major complication of acute coronary syndromes (ACS). We evaluated the involvement of the CD31 molecule in thrombotic risk through the formation of monocyte-platelet (Mo-Plt) aggregates in patients with ACS with no-ST-segment elevation myocardial infarction (NSTEMI) on top of dual anti-platelet therapy (DAPT). We enrolled 19 control (CTRL) subjects, 46 stable angina (SA), and 86 patients with NSTEMI, of which, 16 with Intact Fibrous Cap (IFC) and 19 with Ruptured Fibrous Cap (RFC) as assessed by the Optical Coherence Tomography (OCT). The expression of CD31 on monocytes and platelets was measured. Following the coronary angiography, 52 NSTEMIs were further stratified according to thrombus grade (TG) evaluation. Finally, a series of ex vivo experiments verified whether the CD31 participates in Mo-Plt aggregate formation. In patients with NSTEMI, CD31 was reduced on monocytes and was increased on platelets, especially in NSTEMI presented with RFC plaques compared to those with IFC lesions, and in patients with high TG compared to those with zero/low TG. Ex vivo experiments documented an increase in Mo-Plt aggregates among NSTEMI, which significantly decreased after the CD31 ligation, particularly in patients with RFC plaques. In NSTEMI, CD31 participates in Mo-Plt aggregate formation in spite of optimal therapy and DAPT, suggesting the existence of alternative thrombotic pathways, as predominantly displayed in patients with RFC.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Vinci, Pedicino, Bonanni, d'Aiello, Pisano, Ponzo, Severino, Ciampi, Canonico, Russo, Di Sario, Vergallo, Filomia, Montone, Flego, Stefanini, Piacentini, Conte, Cribari, Massetti, Crea and Liuzzo.)

Details

Language :
English
ISSN :
2297-055X
Volume :
8
Database :
MEDLINE
Journal :
Frontiers in cardiovascular medicine
Publication Type :
Academic Journal
Accession number :
35146002
Full Text :
https://doi.org/10.3389/fcvm.2021.741221